Newlimit Secures $435 Million in Series C Funding
- Newlimit, co-founded by Coinbase CEO Brian Armstrong, raised $435 million in a Series C round.
- The funding round was led by Founders Fund and increased Newlimit’s valuation to approximately $3.1 billion, tripling its previous valuation.
- New investors include Thrive Capital, Greenoaks, and Quiet Capital, with existing backers like Kleiner Perkins and Valor Equity Partners increasing their stakes.
- Founded in 2021, Newlimit focuses on reversing cellular aging through epigenetic reprogramming.
- The company plans to initiate human trials for its first cell-aging reprogramming medicine next year.
Newlimit’s recent funding success highlights significant investor interest in biotechnology focused on longevity science amid fluctuating crypto markets. The company’s approach builds on Nobel-winning research to potentially treat age-related diseases.
With a valuation now at $3.1 billion following the latest raise, Newlimit is well-positioned among top-funded biotech firms aiming to translate laboratory breakthroughs into clinical applications next year. (Source)
